Overview of the Class Action Lawsuit Against Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is currently embroiled in a class action securities lawsuit that has significant implications for its investors. The firm of Levi & Korsinsky, LLP is actively notifying concerned investors about the lawsuit. This legal action centers around claims of securities fraud that reportedly occurred over a specific timeframe.
Details of Allegations Against Regeneron
The lawsuit aims to bring justice for Regeneron investors who have allegedly suffered losses due to misleading financial practices. Between November 2, 2023, and October 30, 2024, it is claimed that the company made various misleading statements about its sales and pricing strategies concerning Eylea, one of its primary products.
Key Allegations in the Lawsuit
The filed suit includes several critical allegations:
- Regeneron allegedly paid credit card fees to distributors under the condition they would not increase costs for Eylea customers using credit cards.
- These payments misleadingly inflated Eylea's reported sales figures, giving the impression of better market performance than reality.
- The company purportedly overstated the Average Selling Price (ASP) reported to federal agencies, leading to potential violations of federal laws.
Implications for Investors
For investors who have seen a decrease in the value of their shares during the defined period, this lawsuit may be a crucial opportunity to seek compensation. Interested parties are encouraged to understand their rights and the potential for recovery.
How Investors Can Participate
Individuals who experienced financial losses related to Regeneron’s stock can submit their information before the deadline to be appointed as lead plaintiff in the action. Importantly, participating in this process does not necessitate being the lead plaintiff to qualify for any recovery.
Supporting Legal Counsel
Levi & Korsinsky has built a reputation over the years, focusing on securing substantial settlements for investors affected by fraudulent corporate practices. With a team of over seventy dedicated professionals, the firm has become a key player in complex securities litigation.
Why Choose Levi & Korsinsky
The firm stands by its track record of success, having successfully navigated many high-stakes securities cases, providing critical support to impacted investors. Those who wish to understand more can contact the firm directly.
Contact Information
Investors may reach out to Levi & Korsinsky, LLP to discuss the lawsuit further or to seek legal assistance. Joseph E. Levi can be reached via telephone at (212) 363-7500 or via email. The firm is located at 33 Whitehall Street, 17th Floor, New York, NY, 10004.
Frequently Asked Questions
What is the basis for the class action against Regeneron?
The lawsuit focuses on misleading statements and concealed pricing practices related to the sale of Eylea, designed to inflate sales figures fraudulently.
Who can join the class action lawsuit?
Investors who suffered losses due to the alleged securities fraud during the specified period can join the lawsuit.
What compensation can investors expect?
The compensation could vary based on individual losses incurred during the relevant timeframe. Each class member may recover damages proportional to their investment loss.
Is there a cost to participate in the lawsuit?
No, there is no cost or obligation for investors to participate in the class action lawsuit.
How can I contact the law firm handling the case?
Investors can contact Levi & Korsinsky, LLP via phone at (212) 363-7500 or email for more details on how to proceed.
